|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We undertook a head-to-head comparison of PSMA-targeted <sup>18</sup>F-DCFPyL PET to Na<sup>18</sup>F PET to determine which modality was more sensitive for the detection of lesions suspicious for bone metastases in a group of patients with metastatic PCa.
|
31451492 |
2020 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging.
|
30620699 |
2020 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agreement between PSMA PET/CT and PSMA-PET/MR was very good for intra-prostatic PSMA-avid foci (K = 0.85) and pelvic lymph nodes (K = 0.98), good for PSMA-avid bone metastases (K = 0.76) and fair for prostatic capsular invasion (K = 0.25) and seminal vesicle involvement (K = 0.31).
|
31332559 |
2020 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Local pelvic lymph node recurrence was detected on F-fluciclovine versus Ga-PSMA-11 in 46.6% versus 50%, in extrapelvic lymph node metastases in 41.4% versus 51.7% and in bone metastases in 25.9% versus 36.2%.
|
31283605 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography.
|
31083752 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
A systematic review and meta-analysis to compare the diagnostic performance of prostate-specific membrane antigen (PSMA)-PET/CT, choline-PET/CT, Sodium Fluoride (NaF) PET/CT, MRI, and bone scintigraphy (BS) in detecting bone metastases in patients with prostate cancer.
|
31127357 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinicians reporting F-PSMA-1007 PET/CT should be aware of this potential pitfall, especially in nontypical trauma pattern (eg, solitary osseous lesion) mimicking bone metastases.
|
30371591 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-PET/CT in comparison with <sup>18</sup>F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
|
30132104 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of these, 50 lesions (11%) were only detectable on PET but not on conventional CT. PET-positive/CT-negative bone metastases demonstrated a significantly lower PSMA uptake compared to PET-positive/CT-positive bone lesions (p < 0.05).
|
31338731 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>68</sup>Ga]PSMA PET/CT is an invaluable imaging modality in the assessment of primary high-risk PCa with great potential for the detection of lymph node spread and bone metastases that would impact the management plan.
|
30215174 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are many options of treating BM, such as chemotherapy, immunotherapy, external beam radiotherapy, bone modifying agents and recently prostate-specific membrane antigen (PSMA) targeted therapies.
|
30843003 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective study, prostate-specific membrane antigen PET/computed tomography was found to be superior to planar bone scintigraphy in the detection of bone metastases.
|
31688499 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
RM2 PET revealed two additional lesions indicative for bone metastases in two patients with multiple PSMA-positive bone metastases, which had no therapeutic consequence.
|
31443113 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recent systematic review also suggests Ga-PSMA PET/CT to be superior to bone scan for identifying bone metastases.
|
31567440 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer patients with known bone metastases underwent PSMA-targeted PET/CT (<sup>18</sup>F-DCFBC or <sup>18</sup>F-DCFPyL) and <sup>18</sup>F-NaF PET/CT.
|
30701023 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT is a useful diagnostic tool in the detection of bone metastases in PC.
|
29362859 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we introduce EBONI (Evaluation of Bone Involvement), a software tool to automatically quantify the bone metastasis load in PSMA PET/CT.
|
29242401 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to evaluate the rate of detection of bone metastases obtained with the prostate-specific membrane antigen (PSMA)-targeting tracer <sup>99m</sup>Tc-MIP-1427, as opposed to conventional bone scanning with <sup>99m</sup>Tc-methylene diphosphonate (<sup>99m</sup>Tc-MDP), in a collective of patients with known advanced-stage osseous metastasized prostate cancer.
|
29371410 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT with [<sup>18</sup>F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
|
29766246 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest the presence of the flare phenomenon to ADT in bone metastases seen on PSMA PET/CT.
|
30222680 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic performance of DW<sub>600</sub>-MRI was significantly lower than that of <sup>68</sup>Ga-PSMA PET/CT and <sup>18</sup>NaF PET/CT for diagnosing bone metastases (p < 0.01), and no significant difference in the AUC was seen between <sup>68</sup>Ga-PSMA PET/CT and <sup>18</sup>NaF PET/CT (p = 0.65).
|
29876619 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga-PSMA avid lesions were most commonly detected in the prostate (n = 193, 43%), loco-regional spread (n = 51, 11%), abdomino-pelvic nodes (n = 129, 29%) and distant metastases (n = 158, 36%), including bone metastases (n = 11, 25%), distant lymphadenopathy (n = 29, 7%) and other organs (n = 18, 4%).
|
30382889 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vertebral Hemangioma Mimicking Bone Metastasis in 68Ga-PSMA Ligand PET/CT.
|
28319497 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present images of Ga-PSMA PET/CT and parameters of response of a 75-year-old heavily pretreated metastatic castration refractory prostate cancer patient with extended bone metastases, showing an extraordinary biochemical response in PSA-levels concordant to SUV decline in bone metastases.
|
27922871 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup> Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.
|
29082604 |
2017 |